Treatment randomization data

The randomization of a patient in a given therapy is the cornerstone of a randomized clinical trial. You may find these data in more than one place. They are often found within some form of Interactive Voice Response System (IVRS), but they may also be found in an electronic file containing the treatment assignments or on the CRF itself. If randomization data are found on the CRF, they usually consist only of the date of randomization for treatment-blinded trials. IVRS data are often found outside the confines of the clinical data management system and usually consist of the following three types of data tables. 

The randomization scheme assigns a therapy randomly across a study population based on various stratification factors such as site, blocking factor, and perhaps subject demographics. There is no actual patient assignment information in this data table. Here is an example of a randomization scheme with a block size of four and a treatment ratio of 2 2  

Notice that treatment is randomly assigned within the given blocks and that there are two placebos and two study medications in each block. Also notice the index variable. The order of the randomization scheme is critical to the usefulness of the scheme, as that is the order in which patients are assigned treatment. If the order of the scheme is altered in any way, then the scheme is damaged. 

The drug kit list is simply a list that shows which drug container/kit label goes with which study medication. It might look something like this  

---

Demographics and Trial-Specific Baseline Data 27 Concomitant or Prior Medication Data 27 Medical History Data 29 Investigational Therapy Drug Log 30 Laboratory Data 31 Adverse Event Data 32 Endpoint/Event Assessment Data 35 Clinical Endpoint Committee (CEC) Data 36 Study Termination Data 37 Treatment Randomization Data 38 Quality-of-Life Data 40... 

The randomization data are used in both efficacy and safety analyses, as they are typically the key stratification variable for the trial. The randomization data allow you to answer the question of whether patients who are getting the study therapy fare better than the alternative. CDISC places treatment assignment information in the special demographics domain. 

Statistical treatments. The data were processed with the SAS statistical package version 6.11, 4 edition (SAS Institute, Inc., Cary, NC). ANOVA analyses were performed at level a = 0.05, according to the model attribute = product + subject + product x subject, with subject as a random effect. Means were compared with the Newman - Keuls multiple comparison test (Student t... 

Although the issues of missing data and intention to treat are closely related, they are not identical. Intention to treat analysis is possible provided outcome and randomization data are not missing and (in its strict sense) impossible if they are. If data are not missing, then even if patients are noncompliant it is possible to analyse them as randomized provided only that their original treatment allocation is known. A per-protocol analysis requires knowledge of compliance. Also, depending on what one means by per protocol, it may or may not require complete outcome data. For example, one could simply say for a per-protocol analysis that one is only interested in patients who not only took the medicine as instructed but also recorded their outcomes. 

The centerpiece of statistical treatment of data is the Gaussian Error function which gives mathematical expression for the behavior of random... 

Multicomponent Systems.— Terpolymerization and reactions involving even more monomers are of enormous practical importance to say nothing of the intrinsic theoretical interest that these complex systems have. In comparison with binary systems the treatment of data and the evaluation of the behaviour of the polymers in relation to composition and structure have received little attention. This is not surprising since the data analysis and structural analysis of multi-component polymerizations and polymers is far from being a simple task. A handful of authors have addressed themselves to the problem in this area, particularly to the difficulties associated with data analysis of statistically random processes. 

In the statistical treatment of data, it is assumed that the handful of replicate experimental results obtained in the laboratory is a minute fraction of the infinite number of results that could, in principle, be obtained gi en infinite time and an infinite amount of sample. Statisticians call the handful of data a sample and view it as a subset of an infinite population, or universe, of data that exists in principle. The laws of statistics apply strictly to populations only when applying t hese laws to a sample of laboratory data, we must assume that the sample is truly representative of the population. Because there is no assurance that this assumption is valid, statements about random errors are necessarily uncertain and must be couched in terms of probabilities. 

If the errors are only random errors and a large number of measurements are taken, the measurements should fall on a normal distribution curve, such as one described in the previous section. We will show that under these conditions the mean value is the best value with a higher precision than any single value. If the errors encountered are mainly systematic errors, no statistical treatment of data can compensate for them. When the errors are entirely random errors, the error probability... 

The Stroke-Thrombolytic Predictive Instrument (Stroke-TPI) has recently been developed in order to provide patient-specific estimates of the probability of a more favorable outcome with rt-PA, and has been proposed as a decision-making aid to patient selection for rt-PA." The estimates from this tool should, however, be treated with caution. The prediction rule is dependent on post hoc mathematical modeling, uses clinical trial data from subjects randomized beyond 3 hours who are not rt-PA-eligible according to FDA labeling and current best practice, and has not been externally validated. It is, therefore, not appropriate to exclude patients from rt-PA treatment based solely on Stroke-TPI predictions. 

Low-molecular-weight heparins and heparinoids are not recommended in the treatment of acute ischemic stroke.11 A meta-analysis was performed using data from 10 randomized controlled trials.19 A non-significant decrease in combined death and disability and a non-significant increase in case fatality and hemorrhage were seen. A reduction in venous thromboembolic events was observed in acute stroke patients however, there was also an increase in extracranial bleeding. 

Topical NSAID preparations are used infrequently in North America. Theoretically, administration via a topical vehicle targets the joints involved and decreases systemic exposure. Randomized, controlled trials, typically of less than 4 weeks duration, have suggested that topical NSAIDs are superior to placebo in relieving OA pain in the first 2 weeks of treatment, but the effect may decline over time.33 Moreover, data are lacking to quantify the theoretical safety advantage of administering NSAIDs topically. 

---